Clinical Trials Browser

OTHER × Ovarian Neoplasms × temsirolimus × Clear all

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01460979 2016-02-29

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

Phase 2 Completed

47 enrolled

Gynecologic

Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Endometrial Neoplasms

NCT00523432 2013-09-05

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

Phase 1 Completed

15 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT00926107 2011-11-10

Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

Phase 2 Terminated

9 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse